All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, What are the advantages of mechanism-based therapies to prevent AML relapse?
What are the advantages of mechanism-based therapies to prevent AML relapse?
In this video, DiNardo provides an overview of mechanism-based therapies for the prevention of relapse in patients with acute myeloid leukemia (AML). She focuses on the incorporation of genomic information in treatment regimen decisions to optimize response for different patient subgroups.
1st NCRI AML academy meeting | What is the optimum treatment strategy for elderly or frail patients with AML?
Prof Courtney DiNardo spoke to us at the 1st NCRI AML academy meeting on the topic of the optimum strategy for the treatment of elderly or...
What is the optimal timepoint for post-transplant MRD assessment?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Andrés Gómez De León, Universidad Autónoma de Nuevo León, Monterrey, MX. We asked, What is the optimal...
Subscribe to get the best content related to AML delivered to your inbox